Related Experiment Video
Updated: Sep 8, 2025
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
Published on: August 22, 2016
Progress on the synthesis of bioengineered heparin as an alternative to animal-derived heparin active pharmaceutical
Xiaohan Jiang1, Bo Zhang2, Xue Cai1
1Zhejiang Key Laboratory of Bioorganic Synthesis, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China; The National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China; Huadong Industrial Technology Institute of Synthetic Biology, Hangzhou, Zhejiang 310014, China; State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China.
Abstract:
Heparin, a clinically essential anticoagulant, has long been derived from animal sources, posing risks of contamination and supply chain instability. Bioengineered heparin, synthesized via microbial fermentation and enzymatic modification, offers a promising alternative with enhanced safety, homogeneity, and scalability. This review highlights recent advances in heparosan biosynthesis, enzymatic sulfation strategies, and analytical characterization for bioengineered heparin. Critical challenges remain, including precise control of heparosan molecular weight, optimization of sulfation patterns, demonstration of structural and functional equivalence to animal-derived heparin, and industrial-scale process validation. By combining synthetic biology with advanced bioprocessing and quality control, structure-defined bioengineered heparin is poised to become a sustainable, high-performance replacement for traditional heparin active pharmaceutical ingredient (API).
